ALZHEIMER DISEASE
Clinical trials for ALZHEIMER DISEASE explained in plain language.
Never miss a new study
Get alerted when new ALZHEIMER DISEASE trials appear
Sign up with your email to follow new studies for ALZHEIMER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Alzheimer's agitation drug safety trial ends early
Disease control TerminatedThis study tested the long-term safety of AXS-05, a combination of dextromethorphan and bupropion, for treating agitation in people with Alzheimer's disease. It enrolled 139 participants who had completed earlier studies. The trial was terminated early, so the full safety picture…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control TerminatedThis early-stage study tested a new drug, ADEL-Y01, in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety and how the drug moves through the body. The trial was stopped early, so results are limited.
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE1 • Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Alzheimer's drug trial halted early after only 8 volunteers
Disease control TerminatedThis study tested a drug called PrimeC in people with mild to moderate Alzheimer's disease. The goal was to see if it is safe and if it helps with thinking and daily activities. The study was stopped early and only 8 people took part, so results are very limited.
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Alzheimer's Tau-Targeting antibody trial halted midway
Disease control TerminatedThis study tested an experimental antibody called JNJ-63733657 in 523 people with early Alzheimer's disease. The antibody aims to clear tau protein clumps in the brain, which are linked to cognitive decline. Participants received either the antibody or a placebo by IV infusion. T…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Alzheimer's drug extension trial halted early — what we know
Disease control TerminatedThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Early safety trial of ION269 for Alzheimer's in down syndrome ends after just one participant
Disease control TerminatedThis early-stage study tested a drug called ION269 in adults with Down syndrome who also showed signs of Alzheimer's disease. The goal was to check if the drug was safe and tolerable when injected into the spinal fluid. Only one person took part, and the study was stopped early, …
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE1 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Alzheimer's drug trial halted early – what we know
Disease control TerminatedThis study tested a drug called varoglutamstat (PQ912) in people with early Alzheimer's disease. The goal was to see if it is safe and if it could slow memory and thinking problems. The trial was stopped early, so we have less information than planned. About 112 people took part,…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: Vivoryon Therapeutics N.V. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called REM0046127 in people with mild to moderate Alzheimer's disease. The goal was to see if it was safe and how it affected brain chemicals and brain wave activity. The trial was stopped early and included only 14 participants instead of t…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: reMYND • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Alzheimer's drug simufilam trial halted Mid-Study
Disease control TerminatedThis study tested a drug called simufilam in over 1,000 people with mild-to-moderate Alzheimer's disease. Participants took either 50 mg, 100 mg, or a placebo twice daily for 76 weeks. The goal was to see if simufilam could slow memory loss and help with daily activities. However…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Eye test may spot Alzheimer's early, study finds
Diagnosis TerminatedThis study explored whether a special eye scan (hyperspectral retinal imaging) can detect beta-amyloid, a protein linked to Alzheimer's disease, in the retina. Researchers aimed to see if this non-invasive test could distinguish people with Alzheimer's from healthy individuals. T…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Center for Eye Research Australia • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis TerminatedThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Can a headband spot Alzheimer's? new study tests brain wave device
Diagnosis TerminatedThis study tested whether a wearable EEG device can help doctors diagnose Alzheimer's disease and mild cognitive impairment. Researchers compared brain wave data from the EEG with standard memory and thinking tests in 148 participants. The goal was to see if the EEG could improve…
Matched conditions: ALZHEIMER DISEASE
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New Alzheimer's pill shows promise in Mid-Stage trial
Symptom relief TerminatedThis study tests whether adding MK-1167 to standard Alzheimer's treatment can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. Researchers will measure changes in cognit…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jul 02, 2026 02:00 UTC
-
Smartphone app aims to ease burden for hispanic dementia caregivers
Symptom relief TerminatedThis study tests a mobile telehealth app called Brain CareNotes designed to help unpaid Hispanic caregivers manage challenging behaviors in people with Alzheimer's or related dementias. The app offers coaching and tools to handle symptoms like agitation or wandering. Researchers …
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief TerminatedThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief TerminatedThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief TerminatedThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief TerminatedThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Sleep therapy tested for Alzheimer's brain fog
Symptom relief TerminatedThis study tested a behavioral program using bright light therapy and sleep coaching to improve sleep and thinking in older adults with mild cognitive impairment or mild Alzheimer's. Only 15 people were enrolled before the study was stopped early. The goal was to see if the progr…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Light helmet for Alzheimer's shows promise, but study cut short
Symptom relief TerminatedThis pilot study tested a special helmet and abdominal panel that shines near-infrared light and uses a static magnetic field on people with mild-to-moderate Alzheimer's disease. The goal was to see if it could safely improve memory and thinking. The study planned to enroll 60 pa…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Can pictures help patients understand research better?
Knowledge-focused TerminatedThis study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Tiny brain wave study aims to sharpen Alzheimer's drug testing
Knowledge-focused TerminatedThis pilot study measured brain activity (EEG) in 6 healthy volunteers while they performed computer tasks that test attention and memory. The goal was to develop better ways to measure thinking skills that could be used in future Alzheimer's drug trials. The study was terminated…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Alzheimer's study probes why patients struggle with daily choices
Knowledge-focused TerminatedThis study looked at how early Alzheimer's disease affects a person's ability to make decisions. Researchers tested 100 people with Alzheimer's and healthy volunteers using memory and thinking tasks, plus a special decision-making test. The goal was to understand which brain func…
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Alzheimer's drug memantine tested on healthy brains – but study halted early
Knowledge-focused TerminatedThis early-stage study aimed to see if taking memantine, an Alzheimer's drug, for 15 days would change certain brain and cognitive markers in healthy young men aged 18-30. The goal was to validate a test battery for future Alzheimer's drug development. However, the study was term…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE1 • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Zapping the brain to save memories: Alzheimer's study tests new approach
Knowledge-focused TerminatedThis study explored whether a non-invasive technique called transcranial magnetic stimulation (TMS) could improve memory in healthy older adults and those with mild memory problems due to Alzheimer's. Researchers used TMS to stimulate brain networks linked to memory and measured …
Matched conditions: ALZHEIMER DISEASE
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Robot watchdog: could a roaming robot prevent falls in dementia care?
Knowledge-focused TerminatedThis study tested whether a robot that moves on its own could patrol nursing home rooms and detect when a resident with Alzheimer's has fallen. The robot was designed to turn on lights, alert staff, and let them see and talk to the resident through its camera and screen. The stud…
Matched conditions: ALZHEIMER DISEASE
Sponsor: Vigorous Mind, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Alzheimer's Anti-Inflammatory trial halted early – what we learned
Knowledge-focused TerminatedThis study tested whether anti-inflammatory drugs could help people with early Alzheimer's or mild cognitive impairment. It was stopped early, so only one drug was studied in 34 participants. The main goal was to measure changes in thinking and memory, but the early termination l…
Matched conditions: ALZHEIMER DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC